Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | HTR1D | P28221 | 1/20 | 0.62 |
| ▸ | HTR1B | P28222 | 1/20 | 0.62 |
| ▸ | HTR1F | P30939 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171841 | 0.89 | HTR6 (1.00) | HTR6HDAC1HDAC2HDAC6HTR1A | |
| SCHEMBL14642142 | 0.78 | HTR6 (1.00) | HTR6HTR1AHTR7 | |
| SCHEMBL949155 | 0.77 | HTR6 (0.65) | HTR6HDAC1HDAC2HDAC6HTR1A | |
| Hydrochloric Acid SCHEMBL946790 | 0.76 | HTR6 (0.63) | HTR6HDAC1HDAC2HDAC6HTR1A | |
| SCHEMBL3322247 | 0.76 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1DHTR1B | |
| SCHEMBL6166554 | 0.76 | HTR6 (0.63) | HTR6HDAC1HDAC2HDAC6HTR1A | |
| SCHEMBL15250049 | 0.75 | HTR6 (1.00) | HTR6 | |
| SCHEMBL5726304 | 0.75 | HTR6 (0.72) | HTR6HTR1AHTR7 | |
| SCHEMBL6335588 | 0.75 | HTR6 (0.60) | HTR6HDAC1HDAC2HDAC6HTR1A | |
| SCHEMBL3248157 | 0.75 | HTR6 (0.68) | HTR6HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| EP-2184064-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184064-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2008060190-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR6, HTR1A, HTR3B | HTR6 1/4885HDAC1 2402/4885HDAC2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.